🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🧵1/ Big news in unresectable stage III NSCLC. The InTRist study is the first randomized trial comparing NAC vs. neoadjuvant chemoimmunotherapy (NAC-ICI) prior to definitive chemoradiotherapy (CRT). Early results are promising. Let’s dig in. 🔍 #LungCancer #RadOnc #ASCO25

🚨CM-577, long term🚨 Resected E/GEJ cancer s/p neoadjuvant CRT + surgery; path residual disease: 🔍Randomized: 12 m nivolumab vs. Surveillance Nivo demonstrated: ✅⬆️DFS ✅⬆️DMFS ✅⬆️OS 🔥PDL1>1 and Esophagus location > benefit 🧐Don’t be fooled be p=0.1 for OS. Study

🔥❓Is Pre-op Chemoradiation the new SoC for locally advanced gallbladder cancer❓🔥 🚨POLCA-GB🚨 T3-4 or N+ GB cancer 🔍Gem-Cis +- CRT CRT Demonstrated: ✅⬆️OS, at median and with substantial separation at tail of curve (read: dcurability) ✅⬆️PFS ✅⬆️Objective response ✅No

Honored to share highlights of Reena Engineer’s presentation of POLCAGB phase III trial at #ASCO2025, a game changer for locally advanced gallbladder cancer Neoadj CRT vs CT alone: 🌟 Nearly doubled mOS (21.8 vs 10.1 months) 🌟 Significantly improved R0 resection (51.6% vs 29.7%)

All You Need to Know: ASCO 🤝 Google Gemini 🧵 A quick breakdown of this bold move to bring AI into evidence-based oncology care — and what it means for the future. Let’s go: #AI #ASCO25 #DigitalHealth ASCO The ASCO Post Google Julie Gralow gilberto lopes Sandip Patel MD FASCO

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

#POLCAGB trial in locally advanced #GallbladderCancer at #ASCO25 Neoadjuvant CisGem +/- ChemoRad 📊OS and ORR improved 🔪84-77% R0/1 👀Higher postoperative complications 🚨Small sample size Changes my practice? Maybe…. In an “adapted” format 🤔 ASCO SEOM Grupo Español de Tratamiento de Tumores Digestivos

Just brand it “Exercizumab!” 😃 In all seriousness, I have been recommending exercise during & after treatment to all my patients who are able to. Great to have Level 1 evidence supporting this strategy. Now need systematic change to upscale & implement. #ASCO25

x.com/i/article/1929…

Drew Moghanaki “possibility VALOR phIII RCT of surgery vs SABR will show no difference in stage I #lungcancer” #radonc #SABR2025 🇨🇦 🟰several studies showing no diff ⬇️ trends for surgery in 🇺🇸 🤔 sampling LNs in solid dom GGO not needed ⚖️ ?benefit of lobectomy nasser altorki

In this month's Radiotherapy & Oncology Van Aken, et al describe a framework to assess interactions and safety of targeted therapes or #Immunotherapy combinations with #Radiotherapy ➡️Pragmatic and biologically informed guidance on how to address 🔗doi.org/10.1016/j.rado…

#RankingQS 🥇| 1ra en Chile y top 3 de Latinoamérica. Un nuevo QS World University Rankings reveló que la #UC sigue liderando las ues. del país y destaca entre las 200 mejores del mundo en cuatro indicadores. 🌎Además, alcanzó el lugar 36º en Reputación Académica. acortar.link/MlMVOs

❓ESTRO & EORTC proposed a classification to standardize reirradiation. But does it predict outcomes or toxicity? 🫁☢️ We applied the classification in thoracic reirradiation for NSCLC. Here’s what we found. 🧵

🌍 How is lung cancer managed around the world? Join us July 3 for a global tumor board tackling real case discussions from diagnosis to survivorship. Featuring experts: Rajat Thawani, Ilit Turgeman, Pramesh CS, Roselle De Guzman, Pablo Munoz Schuffenegger & more! 🔗 bit.ly/43WgnFa

Thank you so much, Simul Parikh, for this excellent blog post on NRG GI-011, which explains our study rationale & logistics perfectly. We hope our trial is of interest to academic practices, community sites, & everything in between V grateful for your support🙏 Full link below

#SABR2025 registrations are open #radonc!! sabrsymposium.com - Come join us Peter Mac Cancer Centre Peter Mac Radiation Oncology on Nov 14th-15th. We have a phenomenal international faculty line up 🇺🇸🇨🇦🇮🇹🇫🇷🇦🇺with Pierre Blanchard, MD Lauren Henke, MD, MSCI, prof. Barbara Jereczek-Fossa, Drew Moghanaki and Melissa O'Neil MRT(T).

Numbers that I am still digesting from todayat @myesmo #ESMOGI25 come from the #KeynoteLecture by #ElisabeteWeiderpass Take home message 1/3 🧵 🌍 Burden of type of GI cancer varies accross countries #ESMOAmbassadors

Tennis and the Physician-Scientist - Lessons from the Court to the Clinic and Lab - Dr. Fabio Moraes oncodaily.com/blog/324126 #OncoDaily #Oncology #Cancer #Health #Medicine #MedX

Could tumour growth speed predict outcomes in oligoprogressive cancer treated with SBRT? In a study of Stereotactic Body Radiotherapy treated patients Aisling Barry & team find tumour-specific growth rate may help identify who benefits most from treatment, irrespective of type.

Excelente review Kimmie Ng, MD, MPH Dana-Farber sobre cáncer gastrointestinal de inicio temprano. Un desafío creciente a nivel global que requiere prioridad para investigación y prevención 👇👇